ESP Diagnostics Limited Information

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.